HC Wainwright & Co. Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $74
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $53 to $74.
HC Wainwright & Co. analyst Douglas Tsao maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $53 to $74.